IgA Pemphigus



Immunoglobulin A (IgA) pemphigus is a group of newly characterized immune-mediated intraepidermal blistering skin diseases. Unlike typical immunoglobulin G (IgG)–mediated pemphigus, IgA pemphigus is characterized by tissue-bound and circulating IgA autoantibodies that target the desmosomal proteins of the epidermis.[1, 2, 3, 4]

Histopathologically, epidermal acantholysis and neutrophil infiltration predominate, hence the synonyms intraepidermal neutrophilic IgA dermatosis, intraepidermal IgA pustulosis, IgA herpetiform pemphigus, and intercellular IgA vesiculopustular dermatosis have been used to describe this group of diseases. No consensus has been reached concerning the nomenclature.

Two subtypes of IgA pemphigus have been identified: subcorneal pustular dermatosis (SPD)–type IgA pemphigus and intraepidermal neutrophilic (IEN)–type IgA dermatosis. Although clinical presentation is similar, these variants have distinct autoantibody target proteins.

Hashimoto et al described an alternative classification for IgA pemphigus, terming the disease “intracellular IgA dermatosis (IAD)”.[5] In addition to the SPD and IEN types, four disease subtypes have been described. Patients with vegetating lesions and pemphigus vegetans–like histology are classified as IgA-pemphigus vegetans (IgA-PVeg). Those with desmoglein-1 or desmoglein-3 target antigens are diagnosed with having IgA-pemphigus foliaceus (IgA-PF) or IgA-pemphigus vulgaris (IgA-PV), respectively. All other cases not meeting these criteria are diagnosed as unclassified IAD.

IgA pemphigus has not been described in animals. Although the term IgA pemphigus has not been established in the veterinary literature, IgA deposition around epidermal cells has been detected by direct immunofluorescence in animals affected with pemphigus foliaceus.

Medscape articles on other variants of pemphigus include Pemphigus Erythematosus, Pemphigus Foliaceus, Pemphigus Herpetiformis, Pemphigus Vulgaris, Drug-Induced Pemphigus, and Paraneoplastic Pemphigus.


The exact pathomechanism of IgA pemphigus is not well defined. According to currently available data, IgA autoantibodies clearly bind to desmosomal components of the epidermis, desmogleins, or desmocollins. The subcorneal pustular dermatosis-type variant exhibits IgA autoantibodies targeting the transmembrane glycoprotein desmocollin 1 present within keratinocyte desmosomes. In contrast, heterogenous target antigens are seen in the intraepidermal neutrophilic IgA dermatosis subtype. IgA autoantibodies in these patients have been shown to bind to desmogleins 1 and 3 in addition to an unspecified nondesmosomal transmembrane protein.[6] The hallmark finding in IgA pemphigus is autoantibodies binding to sites containing the monocyte/granulocyte IgA-Fc receptor (CD89), causing intraepidermal neutrophilic pustules.[7, 8, 9] The direct pathogenic effects of the IgA autoantibodies and exact mechanism of blister formation have not been established.



United States

IgA pemphigus is a group of newly characterized diseases, and its frequency is unknown, although IgA pemphigus has been reported in the United States.


IgA pemphigus is a group of newly characterized diseases, and its frequency is not yet defined. IgA pemphigus has been reported in Asia (including Japan and India[10] ), South America (including Brazil[11] ), and Europe (including Scandinavian countries[12] ). A 2004 article surveying patients affected by autoimmune blistering diseases in Kuwait suggested that IgA pemphigus may be extremely rare in that part of the world.[13]


IgA pemphigus is a rare disease and is newly characterized; therefore, the race distribution is unknown. IgA pemphigus has been reported in American, European, South American, and Asian patients.


The sex distribution of IgA pemphigus is unknown. A review of 28 cases reported from 1982-1997 revealed a male-to-female ratio of 1:1.33.


IgA pemphigus has been reported to occur in persons aged 1 month[14] to 85 years. A review of 28 cases reported from 1982-1997 determined the average age of onset to be 53 years.


Unlike IgG-mediated pemphigus, as a group of diseases, IgA pemphigus usually exhibits a milder clinical phenotype. The prognosis usually is good according to the limited clinical data available.

IgA pemphigus is a superficial blistering disease and usually heals without scarring if treated properly.

Mortality directly resulting from IgA pemphigus has not been reported. In general, the clinical course of IgA pemphigus is less severe than that of IgG-mediated pemphigus, and no significant morbidity exists. In some patients with IgA pemphigus, pruritus is a significant symptom and may interfere with the patient's daily life.

Patient Education

Instruct patients with IgA pemphigus regarding the potential adverse effects of immunosuppressive treatment (eg, prednisone use). Adverse effects may include infection, malignancies, adrenal insufficiency, and osteoporosis.

Teach patients to recognize the symptoms and signs of adverse effects and to report them to the physician if noted. Patients may be inclined to scratch lesions as pruritus may be a prominent symptom. Scratching may cause excoriations, increasing the risk of secondary infection.


Patients affected with IgA pemphigus usually have subacute onset of disease. In more than one half of reported patients, pruritus is present.

Physical Examination

IgA pemphigus is a vesiculopustular skin disease. In general, lesions form within erythematous plaques but also can form in skin without plaques. The initial, clear, fluid-filled blisters associated with IgA pemphigus fill with neutrophils and transform into pustules. Note the following:

In some IgA pemphigus patients, neutrophils settle at the lower part of the blister, forming a hypopyon pattern. Lesions usually became flaccid after an initial tense appearance. Some lesions become crusted and form a herpetiform pattern.[28]

In most IgA pemphigus patients, the trunk and proximal extremities primarily are involved. In some IgA pemphigus patients, scalp and postauricular areas are involved extensively. In some IgA pemphigus patients, intertriginous areas (axillary and inframammary areas) are involved. Mucous membranes, palms, and soles usually are spared. In one patient with IgA pemphigus, involvement of perianal skin and oral mucosa was observed.[29]


The exact pathomechanism of IgA pemphigus is not well defined at the present time. Clearly, IgA autoantibodies are initiated to target desmosomal components, although the initiating mechanism is unknown. At least 3 desmosomal components, including desmoglein 3 (in intraepidermal neutrophilic–type [IEN-type] IgA pemphigus), desmoglein 1, and desmocollin 1 (in subcorneal pustular dermatosis–type [SPD-type] IgA pemphigus foliaceus), have been identified as target antigens in IgA pemphigus.[15, 16, 17, 18, 6, 19, 20] Other unidentified target antigens also may be involved.

A possible role for a specific cytokine has been postulated in IgA pemphigus. Interleukin 5, a TH 2-secreted cytokine that preferentially induces B cells to produce IgA class antibodies, may be activated preferentially in patients with IgA pemphigus.

A possible role for specific T-cell receptors (TCRs) has also been suggested in IgA pemphigus. Gamma/delta TCR-containing T cells, which have been found to be important in influencing mucosal IgA production, may be involved in the IgA pemphigus process.[21]

Additionally, a possible role for the binding site for monocyte/granulocyte IgA-Fc receptor (CD89) in human IgA subclass 1 (IgA1) has been suggested for IgA pemphigus. Human IgA1 antibody has a binding site for the monocyte/granulocyte IgA-Fc receptor (CD89) that is located distally to the hinge region, thus providing a stronger resistance to protease digestion. The protease-resistant property of IgA1 may provide efficient binding of neutrophils, thus allowing the intraepidermal neutrophil infiltration that may contribute to the blistering process.[9]

Postembedding immunoelectron microscopy has localized the target antigen of the SPD-type IgA pemphigus to the extracellular domain of desmocollin, whereas the target antigen of the IEN-type IgA pemphigus was found to be in an intercellular space outside the desmosomal areas. These findings suggest that the pathomechanism of IgA pemphigus involves the weakening of extracellular components of cell-to-cell adhesion molecules.

An association of IgA pemphigus and IgA gammopathy and lung cancer has been reported.[22] Additionally, an association of peripheral T-cell lymphoma complicated by IgA pemphigus has been reported.[23]

The 2005 report of cases of pemphigus characterized by the presence of both IgA and IgG classes of autoantibodies raises the question of whether this IgA/IgG pemphigus is a subset of IgA pemphigus or a novel disease entity.[24]

In some cases of IgA pemphigus, IgA autoantibodies from a single patient were detected against all 3 desmocollin proteins (desmocollins 1, 2, and 3),[25] and, in some patients, IgA autoantibodies from an individual patient were found to recognize both desmocollin and desmoglein proteins.[26] These cases of multiple target antigens identified by patient IgA autoantibodies support the occurrence of epitope spreading, an interesting autoimmune phenomenon in which the inflammatory event "releases" a new target antigen (or antigens) to be recognized by the immune system, leading to a subsequent autoimmunity to the new target antigen (or antigens).[27]

Laboratory Studies

Skin biopsy is performed in IgA pemphigus (see Procedures).

Other Tests

Perform other tests, if available, to document the diagnosis of IgA pemphigus, including immunoblotting, enzyme-linked immunosorbent assay (ELISA), and special immunofluorescence studies.

Immunoblotting in IgA pemphigus

Immunoblotting documents the specific skin antigen recognized by the patient's IgA autoantibodies. Immunoblotting has documented IgA autoantibodies (from 1 patient with IEN-type IgA pemphigus) that target desmosomal component desmoglein 3, which is located at the lower part of epidermis. However, other investigators were unable to detect IgA immunoreactivity to this protein in patient sera; therefore, the significance of the antigen remains unknown.

Enzyme-linked immunosorbent assay in IgA pemphigus

In theory, ELISA should be a good methodology for documenting the specific desmosomal antigen(s) recognized by patient IgA autoantibodies, since it uses native protein and increases detection sensitivity. In 2001, ELISA detected IgA autoantibodies recognizing desmoglein 3 and desmoglein 1 in a small percentage of patients with IgA pemphigus.[5] In many patients, no antigens are detected, suggesting the presence of alternative unidentified target proteins.

Special immunofluorescence tests in IgA pemphigus

Special immunofluorescence tests using cultured cells that express recombinant desmosomal component (desmocollin 1) document the presence of circulating IgA autoantibodies that recognize desmosomal component. Special immunofluorescence tests have documented IgA autoantibodies from patients with SPD-type IgA pemphigus. The tests detected desmosomal component desmocollin 1; however, this test is not generally available.


Skin biopsy is performed and specimens analyzed to establish the diagnosis using histopathology and direct and indirect immunofluorescence. In contrast to classic IgG-mediated pemphigus, acantholysis may be minimal or absent in IgA pemphigus. In the case of patients presenting with extensive pustular eruptions, some authors recommend direct immunofluorescence of perilesional skin as an early screening test, owing to its high detection rate of IgA deposition in the epidermis.[30, 31]

Histopathology is performed on specimens of blistered skin. Histopathology demonstrates an intraepidermal blister, which may be located subcorneally (SPD-type IgA pemphigus), suprabasally, or at mid epidermis (IEN-type IgA pemphigus). Histopathology demonstrates silent or absent acantholysis and is not characteristically observed as in classic pemphigus. A mixed inflammatory infiltrate is observed, including intraepidermal neutrophil infiltration forming a neutrophilic microabscess, which is the hallmark of IgA pemphigus (see the image below).

View Image

Histopathologic examination of a blister lesion obtained from a patient with immunoglobulin A pemphigus shows a suprabasal blistering process, acantho....

Direct immunofluorescence performed on perilesional skin sections is considered the criterion standard test. Direct immunofluorescence documents the immune-mediated disease process. Direct immunofluorescence predominantly detects IgA and, sometimes, to a lesser extent, IgG and complement component C3 deposited at the cell surfaces of the epidermis. Since acantholysis in IgA pemphigus is minimal and sometimes even absent, it can be argued that immunofluorescence should be used as an early screening test for the diagnosis of patients with widespread pustular eruptions.

Indirect immunofluorescence is performed using patient serum on monkey esophagus or other epithelial substrates. Indirect immunofluorescence documents the presence of IgA circulating autoantibodies in patient serum that recognize skin epidermal cell surface components (see the image below). Indirect immunofluorescence with monkey esophagus usually detects IgA circulating autoantibodies in serum that bind to epithelial cell surfaces in approximately half the patients. Intercellular antibody deposition is detected more frequently using human skin for indirect immunofluorescence. Using this method, studies have found intercellular antibody deposition in up to 65% of patients with IgA pemphigus. Titers of IgA pemphigus autoantibodies are much lower than the titers of IgG autoantibodies observed in IgG-mediated pemphigus.

View Image

Indirect immunofluorescence microscopy performed on monkey esophagus substrate (with serum from a patient with immunoglobulin A pemphigus) detects the....

Medical Care

Medical therapy for IgA pemphigus should be directed towards reducing inflammation, because IgA pemphigus represents a group of autoimmune blistering skin diseases manifested clinically as chronic inflammation. Because IgA pemphigus is uncommon, therapy is based on the mechanism of disease and anecdotal reports.

Generally, corticosteroids are the mainstay of treatment for IgA pemphigus. To minimize adverse effects, slow tapering of corticosteroids is advised in order to identify the lowest efficacious dose. Dapsone also may be helpful in IgA pemphigus because of its antineutrophilic effects. Rapid response to treatment with adalimumab and mycophenolate mofetil was reported in 2005.[32] One case report described lesion regression after the addition of azithromycin to a local steroid and keratolytic agent, while another case report described rapid response in SPD-type IgA pemphigus with oral isotretinoin treatment.[33, 34]


Usually, no restrictions are placed on patient activities; however, advise IgA pemphigus patients to avoid contact sports during the active disease state.


Infection may occur secondary to open wounds from the blistering process of IgA pemphigus or secondary to medications used to treat IgA pemphigus.

Malignancies may occur secondary to the chronic inflammatory process or secondary to medications.

Growth retardation is possible secondary to medications used to treat IgA pemphigus during childhood.

Adrenal insufficiency may result secondary to long-term prednisone treatment. Osteoporosis is a complication secondary to long-term prednisone treatment.

Other complications due to long-term therapy, specifically with corticosteroids, include anemia, hypertension, diabetes, and weight gain. Infections with oral candidal organisms and herpes simplex virus may occur.

Medication Summary

In general, corticosteroids are the mainstay of treatment for IgA pemphigus. Dapsone, a medication with antineutrophilic effects, also may be helpful. Anti-inflammatory agents theoretically block the inflammatory process and improve the disease conditions.[33, 35]

Prednisone (Deltasone)

Clinical Context:  Prednisone is an effective treatment for IgA pemphigus. It is an immunosuppressant for the treatment of autoimmune disorders; it may decrease inflammation by reversing increased capillary permeability and suppressing PMN activity. Prednisone stabilizes lysosomal membranes and suppresses lymphocytes and antibody production. Consult a pediatrician before prescribing this medication in children.

Dapsone (Avlosulfon)

Clinical Context:  Dapsone is bactericidal and bacteriostatic against mycobacteria; its mechanism of action is similar to sulfonamides, in which competitive antagonists of PABA prevent formation of folic acid, inhibiting bacterial growth. Dapsone is used alone or in conjunction with other anti-inflammatory medications for treating IgA pemphigus. Consult a pediatrician before prescribing medication in children.

Acitretin (Soriatane)

Clinical Context:  Acitretin is a retinoic acid analog. Its mechanism of action is unknown. Acitretin has been used effectively in several reported cases of IgA pemphigus.

Class Summary

IgA pemphigus is characterized histologically by inflammatory cell (neutrophil) infiltration in the upper epidermis. Anti-inflammatory agents theoretically block the inflammatory process and improve the disease conditions.


Blanca Anais Estupiñan, University of Central Florida College of Medicine

Disclosure: Nothing to disclose.


Neil Sandhu, MD, FAAD, Dermatologist (Medical/Cosmetics) and Mohs Surgeon, Gulf Coast Dermatology

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Edward F Chan, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.


Lawrence S Chan, MD Dr Orville J Stone Professor of Dermatology, Head, Department of Dermatology, University of Illinois College of Medicine

Lawrence S Chan, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Dermatological Association, American Medical Association, Association of Professors of Dermatology, Chicago Dermatological Society, Dermatology Foundation, Illinois State Medical Society, Microcirculatory Society, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Takeji Nishikawa, MD Emeritus Professor, Department of Dermatology, Keio University School of Medicine; Director, Samoncho Dermatology Clinic; Managing Director, The Waksman Foundation of Japan, Inc

Disclosure: Nothing to disclose.


  1. Tsuruta D, Ishii N, Hamada T, Ohyama B, Fukuda S, Koga H, et al. IgA pemphigus. Clin Dermatol. 2011 Jul-Aug. 29(4):437-42. [View Abstract]
  2. Sticherling M, Erfurt-Berge C. Autoimmune blistering diseases of the skin. Autoimmun Rev. 2012 Jan. 11(3):226-30. [View Abstract]
  3. Hashimoto T, Teye K, Ishii N. Clinical and immunological studies of 49 cases of various types of intercellular IgA dermatosis and 13 cases of classical subcorneal pustular dermatosis examined at Kurume University. Br J Dermatol. 2016 Jun 3. [View Abstract]
  4. Ali S, Kelly C, Challacombe SJ, Donaldson AN, Bhogal BS, Setterfield JF. Serum and salivary IgG and IgA antibodies to desmoglein 3 in mucosal pemphigus vulgaris. Br J Dermatol. 2016 Jul. 175 (1):113-21. [View Abstract]
  5. Hashimoto T, Komai A, Futei Y, Nishikawa T, Amagai M. Detection of IgA autoantibodies to desmogleins by an enzyme-linked immunosorbent assay: the presence of new minor subtypes of IgA pemphigus. Arch Dermatol. 2001 Jun. 137(6):735-8. [View Abstract]
  6. Ishii N, Ishida-Yamamoto A, Hashimoto T. Immunolocalization of target autoantigens in IgA pemphigus. Clin Exp Dermatol. 2004 Jan. 29(1):62-6. [View Abstract]
  7. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991 Nov 29. 67(5):869-77. [View Abstract]
  8. Amagai M, Koch PJ, Nishikawa T, Stanley JR. Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J Invest Dermatol. 1996 Feb. 106(2):351-5. [View Abstract]
  9. Carayannopoulos L, Hexham JM, Capra JD. Localization of the binding site for the monocyte immunoglobulin (Ig) A-Fc receptor (CD89) to the domain boundary between Calpha2 and Calpha3 in human IgA1. J Exp Med. 1996 Apr 1. 183(4):1579-86. [View Abstract]
  10. Chowdhury J, Datta PK, Chowdhury SN, Das NK. A Clinicopathological Study of Pemphigus in Eastern India with Special Reference to Direct Immunofluorescence. Indian J Dermatol. 2016 May-Jun. 61 (3):288-94. [View Abstract]
  11. de Oliveira JP, Gabbi TV, Hashimoto T, et al. Two Brazilian cases of IgA pemphigus. J Dermatol. 2003 Dec. 30(12):886-91. [View Abstract]
  12. Gniadecki R, Bygum A, Clemmensen O, Svejgaard E, Ullman S. IgA pemphigus: the first two Scandinavian cases. Acta Derm Venereol. 2002. 82(6):441-5. [View Abstract]
  13. Nanda A, Dvorak R, Al-Saeed K, Al-Sabah H, Alsaleh QA. Spectrum of autoimmune bullous diseases in Kuwait. Int J Dermatol. 2004 Dec. 43(12):876-81. [View Abstract]
  14. Suzuki M, Karube S, Kobori Y, et al. IgA pemphigus occurring in a 1-month-old infant. J Am Acad Dermatol. 2003 Feb. 48(2 Suppl):S22-4. [View Abstract]
  15. Ebihara T, Hashimoto T, Iwatsuki K, et al. Autoantigens for IgA anti-intercellular antibodies of intercellular IgA vesiculopustular dermatosis. J Invest Dermatol. 1991 Oct. 97(4):742-5. [View Abstract]
  16. Hashimoto T, Ebihara T, Nishikawa T. Studies of autoantigens recognized by IgA anti-keratinocyte cell surface antibodies. J Dermatol Sci. 1996 Apr. 12(1):10-7. [View Abstract]
  17. Hashimoto T, Inamoto N, Nakamura K, Nishikawa T. Intercellular IgA dermatosis with clinical features of subcorneal pustular dermatosis. Arch Dermatol. 1987 Aug. 123(8):1062-5. [View Abstract]
  18. Hashimoto T, Kiyokawa C, Mori O, et al. Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J Invest Dermatol. 1997 Aug. 109(2):127-31. [View Abstract]
  19. Karpati S, Amagai M, Liu WL, Dmochowski M, Hashimoto T, Horvath A. Identification of desmoglein 1 as autoantigen in a patient with intraepidermal neutrophilic IgA dermatosis type of IgA pemphigus. Exp Dermatol. 2000 Jun. 9(3):224-8. [View Abstract]
  20. Wang J, Kwon J, Ding X, Fairley JA, Woodley DT, Chan LS. Nonsecretory IgA1 autoantibodies targeting desmosomal component desmoglein 3 in intraepidermal neutrophilic IgA dermatosis. Am J Pathol. 1997 Jun. 150(6):1901-7. [View Abstract]
  21. Fujihashi K, McGhee JR, Kweon MN, et al. gamma/delta T cell-deficient mice have impaired mucosal immunoglobulin A responses. J Exp Med. 1996 Apr 1. 183(4):1929-35. [View Abstract]
  22. Petropoulou H, Politis G, Panagakis P, Hatziolou E, Aroni K, Kontochristopoulos G. Immunoglobulin A pemphigus associated with immunoglobulin A gammopathy and lung cancer. J Dermatol. 2008 Jun. 35(6):341-5. [View Abstract]
  23. Chen L, Yang B, Fan J, Yang K, Liu H, Wu G. Peripheral T-cell lymphoma complicated by immunoglobulin A pemphigus: A case report and literature review. Oncol Lett. 2014 Jul. 8(1):62-66. [View Abstract]
  24. Bruckner AL, Fitzpatrick JE, Hashimoto T, Weston WL, Morelli JG. Atypical IgA/IgG pemphigus involving the skin, oral mucosa, and colon in a child: a novel variant of IgA pemphigus?. Pediatr Dermatol. 2005 Jul-Aug. 22(4):321-7. [View Abstract]
  25. Duker I, Schaller J, Rose C, Zillikens D, Hashimoto T, Kunze J. Subcorneal pustular dermatosis-type IgA pemphigus with autoantibodies to desmocollins 1, 2, and 3. Arch Dermatol. 2009 Oct. 145(10):1159-62. [View Abstract]
  26. Muller R, Heber B, Hashimoto T, et al. Autoantibodies against desmocollins in European patients with pemphigus. Clin Exp Dermatol. 2009 Dec. 34(8):898-903. [View Abstract]
  27. Chan LS, Vanderlugt CJ, Hashimoto T, et al. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol. 1998 Feb. 110(2):103-9. [View Abstract]
  28. Chorzelski TP, Beutner EH, Kowalewski C, et al. IgA pemphigus foliaceus with a clinical presentation of pemphigus herpetiformis. J Am Acad Dermatol. 1991 May. 24(5 Pt 2):839-44. [View Abstract]
  29. Erdag G, Qureshi HS, Greer KE, Patterson JW. Immunoglobulin A pemphigus involving the perianal skin and oral mucosa: an unusual presentation. Cutis. 2007 Sep. 80(3):218-20. [View Abstract]
  30. Neethu KC, Rao R, Balachandran C, Pai S. Juvenile IgA pemphigus: A case report and review of literature. Indian J Dermatol Venereol Leprol. 2016 Jul-Aug. 82 (4):439-42. [View Abstract]
  31. Porro AM, Caetano Lde V, Maehara Lde S, Enokihara MM. Non-classical forms of pemphigus: pemphigus herpetiformis, IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus. An Bras Dermatol. 2014 Jan-Feb. 89 (1):96-106. [View Abstract]
  32. Howell SM, Bessinger GT, Altman CE, Belnap CM. Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol. 2005 Sep. 53(3):541-3. [View Abstract]
  33. Gruss C, Zillikens D, Hashimoto T, et al. Rapid response of IgA pemphigus of subcorneal pustular dermatosis type to treatment with isotretinoin. J Am Acad Dermatol. 2000 Nov. 43(5 Pt 2):923-6. [View Abstract]
  34. Bliziotis I, Rafailidis P, Vergidis P, Falagas ME. Regression of subcorneal pustular dermatosis type of IgA pemphigus lesions with azithromycin. J Infect. 2005 Aug. 51 (2):E31-4. [View Abstract]
  35. Ruiz-Genao DP, Hernandez-Nunez A, Hashimoto T, Amagai M, Fernandez-Herrera J, Garcia-Diez A. A case of IgA pemphigus successfully treated with acitretin. Br J Dermatol. 2002 Nov. 147(5):1040-2. [View Abstract]

Histopathologic examination of a blister lesion obtained from a patient with immunoglobulin A pemphigus shows a suprabasal blistering process, acantholysis, and an inflammatory cell infiltrate containing numerous neutrophils (hematoxylin and eosin, original magnification X50).

Indirect immunofluorescence microscopy performed on monkey esophagus substrate (with serum from a patient with immunoglobulin A pemphigus) detects the immunoglobulin A1 subclass of circulating autoantibodies that label the epithelial cell surfaces of the substrate.

Histopathologic examination of a blister lesion obtained from a patient with immunoglobulin A pemphigus shows a suprabasal blistering process, acantholysis, and an inflammatory cell infiltrate containing numerous neutrophils (hematoxylin and eosin, original magnification X50).

Indirect immunofluorescence microscopy performed on monkey esophagus substrate (with serum from a patient with immunoglobulin A pemphigus) detects the immunoglobulin A1 subclass of circulating autoantibodies that label the epithelial cell surfaces of the substrate.